Temozolomide therapy for patients with non-small cell lung cancer, breast cancer, or melanoma brain metastases.

2010 ◽  
Vol 28 (15_suppl) ◽  
pp. e12539-e12539
Author(s):  
D. R. Naskhletashvili ◽  
V. A. Gorbunova ◽  
M. B. Bychkov ◽  
G. E. Chmutin ◽  
V. B. Karahan ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lung Cancer ◽  
Brain Metastases ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Cancer Breast ◽  
Melanoma Brain Metastases

scholarly journals Systemic therapy of brain metastases: non–small cell lung cancer, breast cancer, and melanoma

2016 ◽  
Vol 19 (1) ◽  
pp. i1-i24 ◽  
Author(s):  
Marc C. Chamberlain ◽  
Christina S. Baik ◽  
Vijayakrishna K. Gadi ◽  
Shailender Bhatia ◽  
Laura Q.M. Chow
Keyword(s):  
Breast Cancer ◽  
Lung Cancer ◽  
Brain Metastases ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Systemic Therapy ◽  
Small Cell ◽  
Small Cell Lung ◽  
Cancer Breast

Response rate and local recurrence after concurrent immune checkpoint therapy and radiotherapy for non–small cell lung cancer and melanoma brain metastases

Cancer ◽  
2020 ◽  
Vol 126 (24) ◽  
pp. 5274-5282 ◽  
Author(s):  
Jack M. Qian ◽  
Allison M. Martin ◽  
Kate Martin ◽  
Lubna Hammoudeh ◽  
Paul J. Catalano ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Local Recurrence ◽  
Brain Metastases ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Immune Checkpoint ◽  
Response Rate ◽  
Small Cell ◽  
Small Cell Lung ◽  
Melanoma Brain Metastases

scholarly journals RADIOSURGERY OF BRAIN METASTASES: RETROSPECTIVE ANALYSIS OF 5 YEAR RESULTS

2020 ◽  
Vol 66 (5) ◽  
pp. 540-548
Author(s):  
M. Girshovich ◽  
O. Ponomareva ◽  
Yu. Melnik ◽  
S. Novikov ◽  
Ye. Khrapovitskaya ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lung Cancer ◽  
Brain Metastases ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Median Overall Survival ◽  
Progression Free Survival ◽  
Small Cell ◽  
Small Cell Lung ◽  
Free Survival

In 5 year 180 patients (89 men and 91 women) underwent radiosurgery of brain metastases. Most patients had breast cancer and less than 5 lesions. Median overall survival (MOS) was 12,5 months, median progression free survival (MPFS) - 6,1 months. Both values were higher in patients with solitary lesions: 22.5 vs 10 months (р=0.00703) and 9 vs 6 months (р=0.02787), respectively.MOS was 18 in women with breast cancer, 12 months in patients with non small cell lung cancer. 8 - with melanoma and only 4 months - for small cell lung cancer. MPFS was significantly shorter for lesions volumes above 15 cm3. In field progression was detected in 37 (2-24 months after treatment) of 180 cases (20,5%). Second radiosurgery was performed in 24 cases.

scholarly journals Implications of Screening for Brain Metastases in Patients With Breast Cancer and Non–Small Cell Lung Cancer

JAMA Oncology ◽  
2018 ◽  
Vol 4 (7) ◽  
pp. 1001 ◽  
Author(s):  
Daniel N. Cagney ◽  
Allison M. Martin ◽  
Paul J. Catalano ◽  
Paul D. Brown ◽  
Brian M. Alexander ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lung Cancer ◽  
Brain Metastases ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung
Sign in / Sign up

Export Citation Format

Share Document